Privacy

Big-Bucks Fund-Raiser Draws Governor’s Backers to Beverly Hills

March 20, 2006  ·  Consumer Watchdog

<p class="source">City News Service</p> <p>"When he ran for office, he said that he was going to make fundamental changes to the system and yet he is perpetuating the system in an even more exacerbated manner by the amount of fund raising he is doing," Jill Furillo, the Southern California director of the California Nurses Association, told KCAL9.</p>

FTCR Letter to Senator John McCain Against His Fundraiser With Arnold

March 16, 2006  ·  Jamie Court

<!-- excerpt -->

Arnold Schwarzenegger & John McCain Spring Into Action ’06 Fundraiser Invitation

March 16, 2006  ·  Consumer Watchdog

<!-- excerpt -->

Raising McCain

March 16, 2006  ·  Judy Dugan

<font face="verdana,sans-serif" size="2">The last time Arnold visited the Beverly Hilton Hotel, it was to declare defeat on all of his ballot initiatives in last November's special election. On Monday he'll return to the hotel to...</font>

Beatty warns Democrats it’s Schwarzenegger they want to beat

March 10, 2006  ·  Consumer Watchdog

<p class="source">Associated Press</p> <p>"I want us to win," Beatty said at a fundraiser for the Foundation for Taxpayer and Consumer Rights, an advocacy group. Echoing a line made famous by President Reagan, he said the party should follow the GOP's lead and embrace the idea that "thou shalt not speak ill of another Democrat."</p>

Business boosts infrastructure;

March 9, 2006  ·  Consumer Watchdog

<h3>The U.S. Chamber of Commerce has entered the fray on the proposal to rebuild the state's roads, levees and schools, paying for a TV ad praising Gov. Schwarzenegger's economic record.</h3><p class="source">Sacramento Bee</p> <p>Jamie Court, president of the Foundation for Taxpayer and Consumer Rights, said the U.S. Chamber of Commerce is serving as a cover for "publicly hated industries like big oil, insurance and HMOs."</p>

Governor’s ties to fitness lobbying group weigh heavy;

March 3, 2006  ·  Consumer Watchdog

<h3>Conflict-of-interest issue hangs over Ohio muscle show</h3><p class="source">THE SAN FRANCISCO CHRONICLE</p> <p>Doug Heller of ArnoldWatch -- a watchdog effort of the Foundation for Taxpayer and Consumer Rights -- said the governor's support for the association last year was disturbing enough. But his activities this coming weekend, a year after the governor declared he had cut financial ties to the Arnold Classic, pose a "lingering question: Is Arnold still working for the muscle industry?"</p>

Fate of stem cell agency falls to court;

February 27, 2006  ·  Consumer Watchdog

<h3>Litigation has scared off investors</h3><p class="source">Monterey County Herald (California)</p> <p>''The stem cell institute's recent responsiveness to public input in a number of areas is encouraging,'' said John Simpson of the Foundation for Taxpayer and Consumer Rights, which is not part of the court case. ''The stem cell oversight committee members finally understand they are a state agency and must involve the public.''</p>

Stem cell transparency

February 20, 2006  ·  Consumer Watchdog

<p class="source">The Los Angeles Times</p> <p>It has taken more pressure from public interest groups than it should have to set the institute on the right path. That's probably because the governing board has no members from such groups, something the Legislature should correct once the three-year moratorium on amending Proposition 71 is over. Still, the board showed that it has learned how to listen and respond, one of its most promising steps so far.</p>

Killer prices?

February 17, 2006  ·  Jamie Court

<p class="source">NPR Marketplace Radio Program</p> <p>Genentech's drug Avastin is a highly effective treatment for colon, breast, and lung cancer. It's also incredibly expensive. Genentech says society has to be willing to pay more for the benefits of life-sustaining drugs, but Commentator Jamie Court says drug companies have a moral obligation not to price them out of reach.</p>

Killer prices?

February 17, 2006  ·  Jamie Court

<h3>Genentech doubling price of cancer drug which clinical trial was government-funded</h3> <p>Genentech's drug Avastin is a highly effective treatment for colon, breast, and lung cancer. It's also incredibly expensive. Genentech says society has to be willing to pay more for the benefits of life-sustaining drugs, but Commentator Jamie Court says drug companies have a moral obligation not to price them out of reach.</p>

The Bonds That Bind

February 16, 2006  ·  Carmen Balber

<font face="verdana,sans-serif" size="2">This letter was sent to Arnold today calling on him to impose a moratorium on fundraising from any construction and development industry interests that might benefit from his proposed...</font>